Creso Pharma’s (ASX:CPH) subsidiary Halucenex handed dealer’s license

• Creso Pharma's (CPH) subsidiary, Halucenex, is being awarded a dealer's licence in Canada, allowing it to advance its clinical trial plans
• Health Canada awarded Halucenex Life Sciences a Controlled Drugs and Substances Dealer’s Licence on August 11
• The licence allows the business to possess, sell, and carry out research on psychedelic substances including psilocybin, ketamine, LSD and MDMA
• Halucenex says the licence allows it to progress its planned phase two clinical trial of psilocybin on treatment-resistant post-traumatic stress disorder

Read the Full Article on The Market Herald here